A Phase 1 interventional study of Cabotegravir sodium (Oral Lead In) and Cabotegravir 400 mg/mL in HIV Infections, sponsored by ViiV Healthcare. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 22nd largest by enrollment, is one of 6 that started in 2020, is one of 10 in phase 1, and was the 21st registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 81st largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2020, is one of 83 in phase 1, and was the 213th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This is an active control, randomized study to investigate the safety, tolerability and PK of repeat dose administration of long-acting CAB 400 mg/mL formulation intramuscular (IM) (gluteus medius and vastus lateralis) and subcutaneous (SC) (abdominal) injections in healthy adult participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exclusion criteria for screening (ECG):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oral dose of CAB 30 milligram (mg) tablet once daily for Days 1 to 28 in the oral lead in phase.
Drug: Cabotegravir sodium (Oral Lead In)
Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 400 milligram per milliliter (mg/mL) (Injection 1: 600 mg and Injection 2: 400 mg respectively) intramuscularly in the gluteus medius, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL
Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 200 mg/mL (Injection 1: 600 mg and Injection 2: 400 mg respectively) intramuscularly in the gluteus medius, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL
Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 400 milligram per milliliter (mg/mL) (Injection 1: 600 mg and Injection 2: 400 mg respectively) subcutaneously in the abdomen, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL
Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 200 mg/mL (Injection 1: 300 mg and Injection 2: 200 mg respectively) subcutaneously in the abdomen, 4 weeks apart, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL
Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 400 milligram per milliliter (mg/mL) (Injection 1: 600 mg and Injection 2: 400 mg respectively) intramuscularly in the lateral thigh, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL
Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 200 mg/mL (Injection 1: 600 mg and Injection 2: 400 mg respectively) intramuscularly in the lateral thigh, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL
Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB400 mg/mL (Injection 1: 400 mg and Injection 2: 200 mg respectively) at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase, with the first injection in the gluteus medius intramuscularly and the second subcutaneously.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL
Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 200 mg/mL (Injection 1: 400 mg and Injection 2: 100 mg respectively) at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase, with the first injection in the gluteus medius intramuscularly and the second subcutaneously.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL
Following receipt of oral CAB 30 in the OLI phase, all participants received two injections of 300 mg of CAB 400 mg/mL subcutaneously, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase, The participants received a topical non-steroidal anti-inflammatory drug (NSAID) and topical steroid placebo with Injection 1, a topical steroid and NSAID placebo with Injection 2.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL · Drug: Topical Non-steroidal anti-inflammatory drug (NSAID) · Drug: Topical steroid · Drug: Topical NSAID placebo · Drug: Topical steroid placebo
Following receipt of oral CAB 30 in the OLI phase, all participants received two injections of 300 mg of CAB 400 mg/mL subcutaneously 4 weeks apart. The participants received a topical steroid and NSAID placebo with injection 1, NSAID and topical steroid placebo with injection 2.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL · Drug: Topical Non-steroidal anti-inflammatory drug (NSAID) · Drug: Topical steroid · Drug: Topical NSAID placebo · Drug: Topical steroid placebo
Following receipt of oral CAB 30 in the OLI phase, participants received one subcutaneous injection of 400 mg of CAB 400 mg/mL along with 5000 units (U) of recombinant human hyaluronidase PH20 (rHuPH20) sequentially.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Following receipt of oral CAB 30 in the OLI phase, participants received one subcutaneous injection of 400 mg of CAB 200 mg/mL along with 5000 U of rHuPH20 sequentially.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Following receipt of oral CAB 30 in the OLI phase, participants received two intramuscular gluteal injections of 800 mg of CAB 400 mg/mL approximately 12 weeks apart.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL
Following receipt of oral CAB 30 in the OLI phase, participants received two intramuscular gluteal injections of 400 mg of CAB 200 mg/mL approximately 12 weeks apart. The dose was matched to the volume of CAB 400 mg/mL administered earlier in the same cohort.
Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL
CAB 30 mg tablets administered orally.
Drug page: Cabotegravir
CAB 400 mg/mL administered intramascularly or subcutaneously.
Drug page: Cabotegravir
CAB 200 mg/mL administered intramascularly or subcutaneously.
NSAID applied topically.
Steroid medication applied topically.
Placebo for NSAID applied topically.
rHuPH20 administered subcutaneously.
Placebo for steroid applied topically.
Part 1 Injection 1: Time of Maximum Observed Plasma Concentration (Tmax) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h
Blood samples were collected for Pharmacokinetic (PK) analysis of CAB. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 1 - Day 1 to Week 4
Part 1 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b
Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 2 - Day 1 to Week 52 follow-up
Part 2 Injection 1: Tmax for CAB 400 mg/ml Formulation for Cohort 5
Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 1 - Day 1 to Week 12
Part 2 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohort 5
Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 2 - Day 1 to Week 52 follow-up
Part 1 Injection 2: Apparent Terminal Phase Half-life (T1/2) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b
Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 2 - Week 4 to Week 52 follow-up
Part 2 Injection 2: T1/2 for CAB 400 mg/ml Formulation for Cohort 5
Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 2 - Week 12 to Week 52 follow-up
Part 1 Injection 2: Terminal Absorption Elimination Rate Constant (KALA) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b
KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected at indicated time points. PK parameters were determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 2 - Week 4 to Week 52 follow-up
Part 2 Injection 2: KALA for CAB 400 mg/ml Formulation for Cohort 5
KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected at indicated time points. PK parameters were determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 2 - Week 12 to Week 52 follow-up
Part 1 Injection 1: Plasma Trough Concentrations (Ctau) of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h
Blood samples were collected for PK analysis of CAB. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR studies.
Time frame: Injection 1 - Day 1 to Week 4
Part 1 Injection 2: Ctau of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b
Blood samples were collected for PK analysis of CAB. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR studies.
Time frame: Injection 2 - Day 1 to Week 4
Part 2 Injection 1: Ctau of CAB 400 mg/ml Formulation for Cohort 5
Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods. Ctau is the trough concentration at the end of the dosing interval. Ctau was expressed as geometric mean. For ATLAS /FLAIR: Historical data of CAB200 group, the geometric mean following dose normalization to 800mg was presented. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR and ECLAIRE studies.
Time frame: Injection 1 - Day 1 to Week 12
Part 1 Injection 1: Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC(0-t)) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b and 4h
Blood samples were collected for PK analysis of CAB. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 1 - Day 1 to Week 4
Part 1 Injection 2: AUC(0-t) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4 and 4b
Blood samples were collected for PK analysis of CAB. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 2 - Day 1 to Week 4
Part 1 Injection 1: Maximum Observed Plasma Concentration (Cmax) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b and 4h
The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 1 - Day 1 to Week 4
Part 1 Injection 2: Cmax of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b
The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
Time frame: Injection 2 - Day 1 to Week 4
Part 1 and Part 2: Number of Participants With Adverse Events (AEs) in Injection Phase and Follow up Phase
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The objective of this analysis is to present the data for participants that received at least an intramuscular or subcutaneous study injection of CAB 400 mg/mL or CAB 200 mg/mL with rHuPH20 formulation.
Time frame: From Injection 1 day 1 up to 52 weeks follow-up
Part 1 and Part 2: Number of Participants With Liver Biochemistry Abnormalities in Injection Phase and Follow up Phase
Blood samples were collected at indicated timepoints to analyze the liver biochemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), Bilirubin and Direct Bilirubin. The objective of this analysis is to present the data for participants that received at least an intramuscular or subcutaneous study injection of CAB 400 mg/mL or CAB 200 mg/mL with rHuPH20 formulation.
Time frame: From Injection 1 day 1 up to 52 weeks follow-up
Cmax for CAB Following Oral 30 mg Administration
Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods.
Time frame: Up to Day 29
Tmax for CAB Following Oral 30 mg Administration
Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods.
Time frame: Up to Day 29
AUC(0-t) for CAB Following Oral 30 mg Administration
Blood samples were collected for PK analysis of CAB after subcutaneous administration. The PK parameters were calculated by non-compartmental analysis.
Time frame: Up to Day 29
Concentration at 24 Hours (C24) for CAB Following Oral 30 mg Administration
Time frame: At 24 hours
Ctau for CAB Following Oral 30 mg Administration
Time frame: Up to 24 hours on day 29 (Oral lead in phase)
Cmax of CAB 200 for Cohort 4h
Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameter was determined using standard non-compartmental methods.
Time frame: Injection 1 - Day 1 to Week 52 follow-up
Tmax of CAB 200 for Cohort 4h
Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameter was determined using standard non-compartmental methods.
Time frame: Injection 1 - Day 1 to Week 52 follow-up
AUC(0-t) of CAB 200 for Cohort 4h
Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameters were determined using standard non-compartmental methods.
Time frame: Injection 1 - Day 1 to Week 52 follow-up
Ctau of CAB 200 for Cohort 4h and in ATLAS/FLAIR Study
Blood samples were collected for PK analysis of CAB after subcutaneous administration. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. Ctau was expressed as geometric mean. For ATLAS /FLAIR: Historical data of CAB200 group, the geometric mean following dose normalization to 400mg was presented.
Time frame: Injection 1 - Day 1 to Week 52 follow-up
T1/2 of CAB 200 & CAB 400 for Cohort 4h
Blood samples were collected for PK analysis of CAB after subcutaneous administration. The PK parameters were calculated by non-compartmental analysis.
Time frame: Injection 1 - Day 1 to Week 52 follow-up
KALA of CAB 200 & CAB 400 for Cohort 4h
KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameters were determined using standard non-compartmental methods.
Time frame: Injection 1 - Day 1 to Week 52 follow-up
| Milestone | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 138 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not randomized to injection phase | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Randomized to injection phase | 125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrawn from study after randomization and before receiving an injection | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 117 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 18 | 2 | 9 | 1 | 13 | 2 | 18 | 2 | 12 | 12 | 9 | 8 | 10 | 1 |
| Completed | 0 | 18 | 2 | 9 | 1 | 13 | 2 | 17 | 2 | 11 | 12 | 9 | 8 | 5 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 5 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Milestone | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 18 | 2 | 9 | 1 | 13 | 2 | 17 | 2 | 11 | 12 | 9 | 8 | 5 | 1 |
| Completed | 0 | 18 | 1 | 8 | 1 | 12 | 1 | 17 | 2 | 10 | 10 | 8 | 6 | 5 | 1 |
| Not completed | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
Blood samples were collected for Pharmacokinetic (PK) analysis of CAB. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| Hour (h) | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 |
|---|---|---|---|---|---|---|---|
| Injection 1 | 197.731 ± 119.0789 | 150.215 ± 27.9825 | 122.009 ± 36.4273 | 145.648 ± 42.1305 | 206.228 ± 100.3655 | 137.853 ± 31.0810 | 131.833 ± 31.3543 |
| Injection 1 [1] | — | — | 132.575 ± 16.1574 | — | — | — | — |
Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| Hour (h) | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) |
|---|---|---|---|---|---|---|
| Part 1 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b | 135.231 ± 39.8828 | 111.656 ± 36.9740 | 108.305 ± 25.7239 | 147.029 ± 35.9930 | 144.092 ± 89.0230 | 155.350 ± 45.5842 |
Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| Hour (h) | Part 2: Cohort 5 (C5) CAB400 |
|---|---|
| Part 2 Injection 1: Tmax for CAB 400 mg/ml Formulation for Cohort 5 | 163.093 ± 21.7123 |
Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| Hour (h) | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) |
|---|---|---|---|---|---|---|
| Part 1 Injection 2: Apparent Terminal Phase Half-life (T1/2) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b | 451.4 ± 58.4 | 333.8 ± 51.1 | 375.1 ± 120.6 | 628.8 ± 84.7 | 2886 ± 42.0 | 645.0 ± 45.9 |
Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
No measurements were reported for this outcome.
KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected at indicated time points. PK parameters were determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| 1/h | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) |
|---|---|---|---|---|---|---|
| Part 1 Injection 2: Terminal Absorption Elimination Rate Constant (KALA) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b | 0.001535 ± 58.4 | 0.002076 ± 51.1 | 0.001847 ± 120.6 | 0.001101 ± 84.9 | 0.001376 ± 94.3 | 0.001074 ± 45.9 |
KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected at indicated time points. PK parameters were determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
No measurements were reported for this outcome.
Blood samples were collected for PK analysis of CAB. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR studies.
| Microgram/ millilitre (μg/mL) | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | ATLAS /FLAIR: Historical Data of CAB200 |
|---|---|---|---|---|---|---|---|---|
| Injection 1 | 2.528 ± 35.1 | 1.907 ± 34.5 | 1.490 ± 176.6 | 1.295 ± 28.6 | 1.220 ± 30.7 | 0.8572 ± 46.6 | 1.371 ± 43.5 | 1.382 ± 71.7406 |
| Injection 1 [1] | — | — | 0.8502 ± 13.0 | — | — | — | — | — |
Blood samples were collected for PK analysis of CAB. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR studies.
| μg/mL | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | ATLAS /FLAIR: Historical Data of CAB200 |
|---|---|---|---|---|---|---|---|
| Part 1 Injection 2: Ctau of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b | 2.853 ± 40.0 | 1.333 ± 60.4 | 1.542 ± 51.6 | 1.290 ± 31.0 | 1.590 ± 26.9 | 1.646 ± 34.8 | 1.840 ± 49.3234 |
Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods. Ctau is the trough concentration at the end of the dosing interval. Ctau was expressed as geometric mean. For ATLAS /FLAIR: Historical data of CAB200 group, the geometric mean following dose normalization to 800mg was presented. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR and ECLAIRE studies.
| μg/mL | Part 2: Cohort 5 (C5) CAB400 | ATLAS /FLAIR: Historical Data of CAB200 | ÉCLAIR: Historical Data of CAB200 |
|---|---|---|---|
| Part 2 Injection 1: Ctau of CAB 400 mg/ml Formulation for Cohort 5 | 0.3787 ± 79.7 | 1.843 ± 71.7406 | 0.3024 ± 157.1133 |
Blood samples were collected for PK analysis of CAB. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| h*μg/mL | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 |
|---|---|---|---|---|---|---|---|
| Injection 1 | 2734 ± 27.0 | 2640 ± 30.2 | 2261 ± 69.9 | 1510 ± 42.9 | 1142 ± 44.0 | 945.2 ± 29.1 | 3133 ± 18.4 |
| Injection 1 [1] | — | — | 1583 ± 10.4 | — | — | — | — |
Blood samples were collected for PK analysis of CAB. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| h*μg/mL | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) |
|---|---|---|---|---|---|---|
| Part 1 Injection 2: AUC(0-t) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4 and 4b | 4731 ± 29.3 | 2050 ± 51.6 | 3170 ± 33.5 | 2417 ± 30.9 | 2409 ± 27.0 | 2649 ± 24.9 |
The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| μg/mL | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 |
|---|---|---|---|---|---|---|---|
| Injection 1 | 6.507 ± 28.7 | 6.760 ± 37.7 | 6.743 ± 75.1 | 3.873 ± 57.0 | 2.750 ± 49.6 | 2.495 ± 28.3 | 8.400 ± 18.4 |
| Injection 1 [1] | — | — | 6.541 ± 7.6 | — | — | — | — |
The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.
| μg/mL | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) |
|---|---|---|---|---|---|---|
| Part 1 Injection 2: Cmax of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b | 7.095 ± 25.8 | 3.538 ± 51.6 | 5.873 ± 75.3 | 3.074 ± 23.8 | 3.718 ± 31.4 | 3.312 ± 36.2 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The objective of this analysis is to present the data for participants that received at least an intramuscular or subcutaneous study injection of CAB 400 mg/mL or CAB 200 mg/mL with rHuPH20 formulation.
| Participants | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 |
|---|---|---|---|---|---|---|---|---|---|
| Injection 1 | 17 | 9 | 11 | 18 | 12 | 12 | 9 | 8 | 10 |
| Injection 1 [1] | — | — | 2 | — | — | — | — | — | — |
| Injection 2 | 15 | 8 | 10 | 16 | 12 | 11 | — | — | — |
| Follow-up | 3 | 2 | 5 | 9 | 2 | 3 | 3 | 3 | 1 |
Blood samples were collected at indicated timepoints to analyze the liver biochemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), Bilirubin and Direct Bilirubin. The objective of this analysis is to present the data for participants that received at least an intramuscular or subcutaneous study injection of CAB 400 mg/mL or CAB 200 mg/mL with rHuPH20 formulation.
| Participants | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 |
|---|---|---|---|---|---|---|---|---|---|
| ALT, Injection 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| ALT, Injection 1 [1] | — | — | 0 | — | — | — | — | — | — |
| ALT, Injection 2 | 0 | 0 | 1 | 0 | 0 | 0 | — | — | — |
| ALT, Follow-up | 2 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| ALP, Injection 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP, Injection 1 [1] | — | — | 0 | — | — | — | — | — | — |
| ALP, Injection 2 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| ALP, Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, Injection 1 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 |
| AST, Injection 1 [1] | — | — | 0 | — | — | — | — | — | — |
| AST, Injection 2 | 1 | 0 | 1 | 0 | 0 | 0 | — | — | — |
| AST, Follow-up | 1 | 0 | 1 | 2 | 0 | 0 | 2 | 1 | 0 |
| Bilirubin, Injection 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Bilirubin, Injection 1 [1] | — | — | 0 | — | — | — | — | — | — |
| Bilirubin, Injection 2 | 0 | 0 | 0 | 0 | 1 | 0 | — | — | — |
| Bilirubin, Follow-up | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Injection 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 |
| Direct Bilirubin, Injection 1 [1] | — | — | 0 | — | — | — | — | — | — |
| Direct Bilirubin, Injection 2 | 0 | 0 | 0 | 2 | 1 | 0 | — | — | — |
| Direct Bilirubin, Follow-up | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods.
| μg/mL | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax for CAB Following Oral 30 mg Administration | 3.728 ± 19.6 | 3.921 ± 15.3 | 5.007 ± 8.1 | 4.526 ± 18.0 | 4.090 ± NA | 3.573 ± 20.6 | 3.841 ± 6.1 | 3.864 ± 20.1 | 2.863 ± 26.0 | 3.428 ± 29.2 | 3.975 ± 27.0 | 3.393 ± 41.9 | 3.929 ± 23.4 | 3.243 ± 53.8 | 4.030 ± NA |
Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods.
| Hour (h) | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax for CAB Following Oral 30 mg Administration | 1.9 ± 81.8 | 2.031 ± 58.9 | 1.000 ± NA | 1.957 ± 54.1 | 1.000 ± NA | 1.692 ± 67.6 | 2.000 ± 127.0 | 2.010 ± 54.1 | 1.732 ± 91.0 | 2.982 ± 58.3 | 1.528 ± 51.1 | 1.937 ± 55.7 | 2.113 ± 57.8 | 2.179 ± 78.0 | 1.067 ± NA |
Blood samples were collected for PK analysis of CAB after subcutaneous administration. The PK parameters were calculated by non-compartmental analysis.
| h*μg/mL | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC(0-t) for CAB Following Oral 30 mg Administration | 50.725 ± 18.1 | 60.91 ± 19.7 | 69.29 ± 1.7 | 70.31 ± 17.2 | 60.62 ± NA | 56.03 ± 20.0 | 58.10 ± 9.3 | 58.52 ± 18.9 | 46.34 ± 26.4 | 57.42 ± 20.7 | 59.33 ± 26.5 | 52.36 ± 43.5 | 63.58 ± 22.8 | 45.79 ± 54.2 | 57.61 ± NA |
| μg/mL | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concentration at 24 Hours (C24) for CAB Following Oral 30 mg Administration | 1.5450422 ± 19.3 | 1.971 ± 20.6 | 2.125 ± 1.0 | 2.229 ± 16.7 | 1.760 ± NA | 1.748 ± 25.4 | 1.744 ± 5.3 | 1.808 ± 25.3 | 1.489 ± 12.9 | 2.059 ± 19.2 | 2.001 ± 39.2 | 1.671 ± 41.1 | 2.033 ± 25.8 |
| μg/mL | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ctau for CAB Following Oral 30 mg Administration | 5.0488137 ± 49.6 | 3.629 ± 158.1 | — | 3.074 ± 366.6 | 2.230 ± NA | 5.456 ± 42.2 | 3.576 ± 23.7 | 5.430 ± 44.3 | 4.468 ± 3.8 | 4.169 ± 76.0 | 4.667 ± 31.9 | 4.811 ± 51.1 | 6.966 ± 59.3 | 3.596 ± 60.5 | — |
Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameter was determined using standard non-compartmental methods.
| μg/mL | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 |
|---|---|
| Cmax of CAB 200 for Cohort 4h | 2.507 ± 29.9 |
Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameter was determined using standard non-compartmental methods.
| Hour (h) | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 |
|---|---|
| Tmax of CAB 200 for Cohort 4h | 175.064 ± 41.1 |
Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameters were determined using standard non-compartmental methods.
| h*μg/mL | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 |
|---|---|
| AUC(0-t) of CAB 200 for Cohort 4h | 3087 ± 13.8 |
Blood samples were collected for PK analysis of CAB after subcutaneous administration. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. Ctau was expressed as geometric mean. For ATLAS /FLAIR: Historical data of CAB200 group, the geometric mean following dose normalization to 400mg was presented.
| μg/mL | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | ATLAS /FLAIR: Historical Data of CAB200 |
|---|---|---|
| Ctau of CAB 200 for Cohort 4h and in ATLAS/FLAIR Study | 1.008 ± 36.6 | 0.9216 ± 71.7406 |
Blood samples were collected for PK analysis of CAB after subcutaneous administration. The PK parameters were calculated by non-compartmental analysis.
| Hour (h) | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 |
|---|---|---|
| T1/2 of CAB 200 & CAB 400 for Cohort 4h | 1233 ± 20.6 | 210.8 ± 42.0 |
KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameters were determined using standard non-compartmental methods.
| 1/h | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 |
|---|---|---|
| KALA of CAB 200 & CAB 400 for Cohort 4h | 0.0005615 ± 20.6 | 0.003288 ± 42.0 |
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 of OLI Phase up to approximately Week 52 of Follow-up Phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Cabotegravir (CAB) 30 | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Part 1: Cohort 1 (C1) CAB400 | 0/18 (0%) | 0/18 (0%) | 18/18 (100%) |
| Part 1: Cohort 1 (C1) CAB200 | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Part 1: Cohort 2 (C2) CAB400 | 0/11 (0%) | 0/11 (0%) | 10/11 (90.9%) |
| Part 1: Cohort 2 (C2) CAB200 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part 1: Cohort 3 (C3) CAB400 | 0/16 (0%) | 2/16 (12.5%) | 15/16 (93.8%) |
| Part 1: Cohort 3 (C3) CAB200 | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Part 1: Cohort 4 (C4) CAB400 | 0/18 (0%) | 0/18 (0%) | 18/18 (100%) |
| Part 1: Cohort 4 (C4) CAB200 | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Part 1: Cohort 4b Group 1 (C4b G1) | 0/13 (0%) | 0/13 (0%) | 13/13 (100%) |
| Part 1: Cohort 4b Group 2 (C4b G2) | 0/14 (0%) | 1/14 (7.1%) | 13/14 (92.9%) |
| Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Part 2: Cohort 5 (C5) CAB400 | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Part 2: Cohort 5 (C5) CAB200 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hiatus herniaGastrointestinal disorders | 0/13 | 0/18 | 0/2 | 0/11 | 0/1 | 0/16 | 0/2 | 0/18 | 0/2 | 0/13 | 1/14 | 0/9 | 0/8 | 0/10 | 0/1 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/13 | 0/18 | 0/2 | 0/11 | 0/1 | 1/16 | 0/2 | 0/18 | 0/2 | 0/13 | 0/14 | 0/9 | 0/8 | 0/10 | 0/1 |
| AnxietyPsychiatric disorders | 0/13 | 0/18 | 0/2 | 0/11 | 0/1 | 1/16 | 0/2 | 0/18 | 0/2 | 0/13 | 0/14 | 0/9 | 0/8 | 0/10 | 0/1 |
| Event | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 0/13 | 18/18 | 2/2 | 8/11 | 1/1 | 12/16 | 2/2 | 17/18 | 1/2 | 12/13 | 12/14 | 9/9 | 8/8 | 10/10 | 1/1 |
| Injection site noduleGeneral disorders | 0/13 | 10/18 | 0/2 | 4/11 | 1/1 | 1/16 | 0/2 | 9/18 | 0/2 | 7/13 | 5/14 | 2/9 | 0/8 | 2/10 | 1/1 |
| Injection site erythemaGeneral disorders | 0/13 | 8/18 | 1/2 | 8/11 | 0/1 | 4/16 | 1/2 | 18/18 | 1/2 | 12/13 | 12/14 | 9/9 | 8/8 | 4/10 | 0/1 |
| Injection site indurationGeneral disorders | 0/13 | 6/18 | 0/2 | 5/11 | 0/1 | 3/16 | 2/2 | 8/18 | 1/2 | 3/13 | 2/14 | 0/9 | 1/8 | 0/10 | 0/1 |
| Injection site haemorrhageGeneral disorders | 0/13 | 0/18 | 0/2 | 1/11 | 1/1 | 0/16 | 0/2 | 0/18 | 0/2 | 0/13 | 0/14 | 0/9 | 0/8 | 0/10 | 0/1 |
| White blood cell count increasedInvestigations | 0/13 | 0/18 | 0/2 | 0/11 | 0/1 | 0/16 | 0/2 | 1/18 | 0/2 | 0/13 | 0/14 | 1/9 | 0/8 | 0/10 | 1/1 |
| AccidentInjury, poisoning and procedural complications | 0/13 | 0/18 | 0/2 | 0/11 | 0/1 | 0/16 | 0/2 | 0/18 | 0/2 | 0/13 | 0/14 | 0/9 | 0/8 | 0/10 | 1/1 |
| Injection site warmthGeneral disorders | 0/13 | 5/18 | 0/2 | 2/11 | 0/1 | 3/16 | 0/2 | 10/18 | 0/2 | 12/13 | 11/14 | 8/9 | 6/8 | 6/10 | 0/1 |
| Injection site swellingGeneral disorders | 0/13 | 2/18 | 0/2 | 4/11 | 0/1 | 6/16 | 0/2 | 10/18 | 0/2 | 10/13 | 9/14 | 7/9 | 7/8 | 7/10 | 0/1 |
| Injection site pruritusGeneral disorders | 0/13 | 1/18 | 0/2 | 5/11 | 0/1 | 4/16 | 0/2 | 6/18 | 0/2 | 7/13 | 5/14 | 7/9 | 7/8 | 0/10 | 0/1 |
| Age, Customized(Participants) | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adult (18-64 years) | 13 | 18 | 2 | 11 | 1 | 16 | 2 | 18 | 2 | 13 | 14 | 9 | 8 | 10 | 1 | 138 |
| Sex: Female, Male(Participants) | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 7 | 12 | 1 | 3 | 0 | 6 | 1 | 9 | 1 | 5 | 5 | 4 | 6 | 2 | 0 | 62 |
| Male | 6 | 6 | 1 | 8 | 1 | 10 | 1 | 9 | 1 | 8 | 9 | 5 | 2 | 8 | 1 | 76 |
| Race/Ethnicity, Customized(Participants) | Oral Cabotegravir (CAB) 30 | Part 1: Cohort 1 (C1) CAB400 | Part 1: Cohort 1 (C1) CAB200 | Part 1: Cohort 2 (C2) CAB400 | Part 1: Cohort 2 (C2) CAB200 | Part 1: Cohort 3 (C3) CAB400 | Part 1: Cohort 3 (C3) CAB200 | Part 1: Cohort 4 (C4) CAB400 | Part 1: Cohort 4 (C4) CAB200 | Part 1: Cohort 4b Group 1 (C4b G1) | Part 1: Cohort 4b Group 2 (C4b G2) | Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 | Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 | Part 2: Cohort 5 (C5) CAB400 | Part 2: Cohort 5 (C5) CAB200 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| De-identified | 11 | 17 | 2 | 11 | 1 | 16 | 2 | 15 | 1 | 12 | 13 | 8 | 8 | 10 | 1 | 128 |
| Other, unspecified | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jul 2020 to primary completion in May 2023, 33 months.
Results were first posted in May 2026, 3 years after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 33 months is above that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir